TrovaGene Inc—formerly Xenomics Inc—a developer of transrenal molecular diagnostics, announced that LabCorp and InVivoScribe Technologies have notified the company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis of acute myelogenous leukemia (AML).
TrovaGene has sublicensed the technology to these labs and will receive royalties based upon their testing revenue.
“These new tests are expected to improve patient outcomes by helping to monitor effective treatment decisions.”
“We are pleased that these two companies have begun offering this valuable new testing service based on our patented NPM1 technology,” said Bruce A. Huebner, TrovaGene’s President and CEO. “These new tests are expected to improve patient outcomes by helping to monitor effective treatment decisions.”
Acute myelogenous leukemia is a cancer of the bone marrow in which the rapid proliferation of abnormal cells interferes with normal blood cell production. There are over 13,000 new cases of AML each year in the US and 200,000 new cases worldwide. It is the deadliest form of leukemia causing more than 9,000 deaths per year in the US. The NPM1 mutation status is associated with good disease prognosis and may influence treatment options. This testing is now included in the recommendations of the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines in Oncology. The NPM1 mutation is also used as a patient-specific biomarker for monitoring minimal residual disease (MRD) and early detection of recurrence after treatment.